Stock APVO APTEVO THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Aptevo Therapeutics Inc.

Equities

APVO

US03835L3069

Real-time Estimate Cboe BZX
Other stock markets
 01:19:42 2024-04-29 pm EDT 		5-day change 1st Jan Change
0.754 USD +6.78% Intraday chart for Aptevo Therapeutics Inc. 0.00% -91.13%
Apr. 11 US Equity Markets Close Mixed After March Producer Price Inflation Data MT
Apr. 11 Top Midday Decliners MT

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Wall Street Set to Open Higher as Investors Await Inflation Data, Fed Rate Decision in Coming Days
MT
US Futures Move Modestly Higher Monday Ahead of Inflation Data Tuesday, Fed Rate Decision Meeting Conclusion Wednesday
MT
Aptevo Therapeutics Inc. Announces APVO436, in Combination with Venetoclax and Azacitidine, Achieved a 100% Clinical Benefit Rate in Venetoclax Treatment Naïve AML Patients
CI
Piper Sandler Adjusts Price Target on Aptevo Therapeutics to $20 From $69, Reiterates Overweight Rating
MT
Roth Capital Adjusts Aptevo Therapeutics' Price Target to $36 From $50, Reiterates Buy Rating
MT
APTEVO THERAPEUTICS : Roth Capital Adjusts Aptevo Therapeutics PT to $50 From $64, Maintains Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. APVO Stock
  4. News Aptevo Therapeutics Inc.
  5. Analyst Reco.